6-Methyl-MDA

6-Methyl-MDA
Systematic (IUPAC) name
1-(6-methyl-1,3-benzodioxol-5-yl)propan-2-amine
Clinical data
  • Uncontrolled (but may be covered under the Federal Analogue Act in the United States and under similar bills in other countries)
Oral
Identifiers
None
PubChem CID 10511982
ChemSpider 8687383 Yes
ChEMBL CHEMBL6376 Yes
Chemical data
Formula C11NO2
193.24 g/mol
 Yes (what is this?)  (verify)

6-Methyl-3,4-methylenedioxyamphetamine (6-Methyl-MDA) is an entactogen and psychedelic drug of the amphetamine class.[1] It was first synthesized in the late 1990s by a team including David E. Nichols at Purdue University while investigating derivatives of MDA and MDMA.[1]

6-Methyl-MDA has IC50 values of 783nM, 28,300nM, and 4,602nM for inhibiting the reuptake of serotonin, dopamine, and norepinephrine in rat synaptosomes.[1] In animal studies it substitutes for MBDB, MMAI, LSD, and DOI, though not amphetamine, but only partially and at high doses.[1] Thus, while several-fold less potent than its analogues 2-methyl-MDA and 5-methyl-MDA, and approximately half as potent as MDA, 6-methyl-MDA is still significantly active,[1] and appropriate doses may be similar to or somewhat higher than those of MDMA.

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 Parker MA, Marona-Lewicka D, Kurrasch D, Shulgin AT, Nichols DE (March 1998). "Synthesis and pharmacological evaluation of ring-methylated derivatives of 3,4-(methylenedioxy)amphetamine (MDA)". Journal of Medicinal Chemistry 41 (6): 1001–5. doi:10.1021/jm9705925. PMID 9526575.